Wockhardt Limited (WOCKPHARMA.BO)
INR 1319.3
(9.99%)
INR 1319.3
(9.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 27.89 Billion INR | 5.74% |
| 2022 | 26.46 Billion INR | -17.57% |
| 2021 | 32.1 Billion INR | 18.93% |
| 2020 | 26.99 Billion INR | -4.73% |
| 2019 | 28.33 Billion INR | -20.14% |
| 2018 | 35.47 Billion INR | -9.22% |
| 2017 | 39.07 Billion INR | -2.66% |
| 2016 | 40.14 Billion INR | -9.85% |
| 2015 | 44.53 Billion INR | -0.63% |
| 2014 | 44.81 Billion INR | -7.22% |
| 2013 | 48.3 Billion INR | -13.89% |
| 2012 | 56.09 Billion INR | 28.94% |
| 2011 | 43.5 Billion INR | 15.97% |
| 2010 | 37.51 Billion INR | -16.67% |
| 2009 | 45.01 Billion INR | 25.4% |
| 2008 | 35.89 Billion INR | 44.12% |
| 2007 | 24.9 Billion INR | 44.06% |
| 2006 | 17.29 Billion INR | 22.36% |
| 2005 | 14.13 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 7.39 Billion INR | 5.57% |
| 2023 Q4 | 7 Billion INR | -0.14% |
| 2023 FY | 27.98 Billion INR | 5.74% |
| 2023 Q1 | 6.44 Billion INR | -4.31% |
| 2023 Q2 | 7.53 Billion INR | 16.93% |
| 2023 Q3 | 7.01 Billion INR | -6.91% |
| 2022 FY | 26.46 Billion INR | -17.57% |
| 2022 Q1 | 5.95 Billion INR | -6.23% |
| 2022 Q2 | 6.79 Billion INR | 14.12% |
| 2022 Q3 | 6.99 Billion INR | 2.95% |
| 2022 Q4 | 6.73 Billion INR | -3.72% |
| 2021 Q3 | 8.54 Billion INR | -0.93% |
| 2021 FY | 32.1 Billion INR | 18.93% |
| 2021 Q1 | 8.6 Billion INR | 38.07% |
| 2021 Q2 | 8.62 Billion INR | 0.23% |
| 2021 Q4 | 6.34 Billion INR | -25.7% |
| 2020 Q4 | 6.22 Billion INR | -18.47% |
| 2020 FY | 26.99 Billion INR | -4.73% |
| 2020 Q3 | 7.64 Billion INR | 7.0% |
| 2020 Q2 | 7.14 Billion INR | 19.35% |
| 2020 Q1 | 5.98 Billion INR | 100.37% |
| 2019 Q3 | 7.48 Billion INR | 9.62% |
| 2019 Q2 | 6.82 Billion INR | -5.88% |
| 2019 FY | 28.33 Billion INR | -20.14% |
| 2019 Q4 | 2.98 Billion INR | -60.11% |
| 2019 Q1 | 7.25 Billion INR | -24.47% |
| 2018 Q1 | 10.07 Billion INR | -1.04% |
| 2018 FY | 35.47 Billion INR | -9.22% |
| 2018 Q4 | 9.6 Billion INR | -8.14% |
| 2018 Q3 | 10.45 Billion INR | -7.09% |
| 2018 Q2 | 11.25 Billion INR | 11.71% |
| 2017 Q1 | 8.91 Billion INR | 3.19% |
| 2017 FY | 39.07 Billion INR | -2.66% |
| 2017 Q4 | 10.18 Billion INR | 1.29% |
| 2017 Q3 | 10.05 Billion INR | -1.66% |
| 2017 Q2 | 10.22 Billion INR | 14.73% |
| 2016 Q4 | 8.63 Billion INR | -13.26% |
| 2016 FY | 40.14 Billion INR | -9.85% |
| 2016 Q2 | 10.64 Billion INR | -2.4% |
| 2016 Q1 | 10.9 Billion INR | 7.98% |
| 2016 Q3 | 9.95 Billion INR | -6.49% |
| 2015 Q3 | 10.74 Billion INR | -12.61% |
| 2015 FY | 44.53 Billion INR | -0.63% |
| 2015 Q1 | 11.38 Billion INR | -1.86% |
| 2015 Q2 | 12.29 Billion INR | 7.97% |
| 2015 Q4 | 10.1 Billion INR | -5.98% |
| 2014 Q1 | 9.91 Billion INR | -4.57% |
| 2014 FY | 44.81 Billion INR | -7.22% |
| 2014 Q4 | 11.6 Billion INR | -16.03% |
| 2014 Q3 | 13.82 Billion INR | 45.81% |
| 2014 Q2 | 9.47 Billion INR | -4.37% |
| 2013 FY | 48.3 Billion INR | -13.89% |
| 2013 Q4 | 10.38 Billion INR | -15.99% |
| 2013 Q1 | 13.58 Billion INR | -8.56% |
| 2013 Q3 | 12.36 Billion INR | 3.29% |
| 2013 Q2 | 11.96 Billion INR | -11.88% |
| 2012 Q4 | 14.85 Billion INR | 3.52% |
| 2012 Q1 | 13.41 Billion INR | -6.77% |
| 2012 FY | 56.09 Billion INR | 28.94% |
| 2012 Q2 | 13.47 Billion INR | 0.45% |
| 2012 Q3 | 14.35 Billion INR | 6.5% |
| 2011 Q4 | 14.38 Billion INR | 26.12% |
| 2011 FY | 43.5 Billion INR | 15.97% |
| 2011 Q3 | 11.4 Billion INR | 0.0% |
| 2010 FY | 37.51 Billion INR | -16.67% |
| 2009 FY | 45.01 Billion INR | 25.4% |
| 2008 FY | 35.89 Billion INR | 44.12% |
| 2007 FY | 24.9 Billion INR | 44.06% |
| 2006 FY | 17.29 Billion INR | 22.36% |
| 2005 FY | 14.13 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 94.249% |
| NATCO Pharma Limited | 40.02 Billion INR | 30.31% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -165.277% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -975.82% |
| Achyut Healthcare Limited | 61.36 Million INR | -45346.398% |
| Ajanta Pharma Limited | 42.08 Billion INR | 33.733% |
| Alkem Laboratories Limited | 126.67 Billion INR | 77.983% |
| Alpa Laboratories Limited | 1.08 Billion INR | -2464.857% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 54.369% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -115.279% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 90.284% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -489.12% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -262.093% |
| Brooks Laboratories Limited | 794.86 Million INR | -3408.79% |
| Divi's Laboratories Limited | 78.45 Billion INR | 64.449% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 90.009% |
| Eris Lifesciences Limited | 20.09 Billion INR | -38.815% |
| FDC Limited | 19.42 Billion INR | -43.545% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 76.391% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -22.152% |
| Granules India Limited | 45.06 Billion INR | 38.11% |
| Gufic Biosciences Limited | 8.06 Billion INR | -245.744% |
| Hester Biosciences Limited | 3.04 Billion INR | -815.789% |
| Indoco Remedies Limited | 17.89 Billion INR | -55.858% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -117.738% |
| Ipca Laboratories Limited | 76.22 Billion INR | 63.411% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -1236.355% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -5431.371% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -2573.12% |
| Laurus Labs Limited | 50.01 Billion INR | 44.24% |
| Lupin Limited | 200.1 Billion INR | 86.063% |
| Mankind Pharma Limited | 103.34 Billion INR | 73.013% |
| Medicamen Biotech Limited | 1.79 Billion INR | -1455.44% |
| Medico Remedies Limited | 1.44 Billion INR | -1824.501% |
| Megasoft Limited | 373.95 Million INR | -7358.157% |
| Piramal Pharma Limited | 81.71 Billion INR | 65.868% |
| RPG Life Sciences Limited | 5.82 Billion INR | -379.168% |
| Sigachi Industries Limited | 3.98 Billion INR | -599.074% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -3591.825% |
| Unichem Laboratories Limited | 16.57 Billion INR | -68.274% |
| Wanbury Limited | 5.75 Billion INR | -384.496% |
| Windlas Biotech Limited | 6.3 Billion INR | -342.028% |
| ZIM Laboratories Limited | 3.67 Billion INR | -659.068% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 85.338% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -142.256% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -562.108% |
| Bal Pharma Limited | 3.39 Billion INR | -722.181% |
| Strides Pharma Science Limited | 40.51 Billion INR | 31.155% |
| Venus Remedies Limited | 5.91 Billion INR | -371.553% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -53.621% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -65.609% |
| Shilpa Medicare Limited | 11.51 Billion INR | -142.184% |
| Aarti Drugs Limited | 25.28 Billion INR | -10.299% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | -31.621% |
| Suven Life Sciences Limited | 116.92 Million INR | -23752.081% |
| Ind-Swift Limited | 5.02 Billion INR | -455.06% |
| Valiant Laboratories Limited | 1.82 Billion INR | -1431.936% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 19.953% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -125.212% |
| Themis Medicare Limited | 3.81 Billion INR | -630.562% |
| Hikal Limited | 17.84 Billion INR | -56.282% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 73.702% |
| Sequent Scientific Limited | 13.69 Billion INR | -103.617% |
| Novartis India Limited | 3.35 Billion INR | -732.363% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 58.391% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -6866.352% |
| Neuland Laboratories Limited | 15.58 Billion INR | -78.945% |
| Morepen Laboratories Limited | 17.01 Billion INR | -63.876% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -1706.669% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -656.657% |